Statins × adverse events & safety

TrialClinical nephrology2014

Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients.

Chistoph Wanner et al.PubMed ↗Publisher ↗

What the trial testedas reported · 2014

Range includes no effect

No clear effect on lipids

+0.60percentage points−5.70 to +4.50

As reported

difference 0.6 %, 95% CI −5.70 to 4.50

No range given

Reported lower adverse events & safety, no range given

−37.4percentage points

As reported

difference −37.4 %, no interval

Two numbers in the abstract

the abstract, start to end

changes -29.5% vs. -28.9%; difference 0.6%, 95% CI -5.7, 4.5).

change +4.4% vs. +41.7%; difference -37.4%; p < 0.001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Lipids
0.6−5.70 to 4.50
Adverse events & safety
−37.4
StatinsLipidsAdverse events & safety

Statins × adverse events & safetyharms?mixed

unlikelylikely
0.160.20 without it

Statins × lipidshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

1 paper cites it

2014
2015
2016
2017
2018
2019
2020
2021
2022
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 25079861